Margarida Maia, PhD, science writer —

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

Application of Parkinson’s therapy IPX203 resubmitted to FDA

Amneal Pharmaceuticals has resubmitted its application for IPX203, an investigational extended-release oral formulation of carbidopa and levodopa for treating Parkinson’s disease. The move follows a request by the U.S. Food and Drug Administration (FDA) in July 2023 for more information on the safety of IPX203’s carbidopa component…

Vyalev, steady levodopa/carbidopa infusion, now available in Canada

Vyalev, a brand name for AbbVie’s ABBV-951 (foslevodopa/foscarbidopa), is now available in Canada as a continuous, subcutaneous (under-the-skin) infusion treatment for people with advanced Parkinson’s disease and motor symptoms that cannot be well controlled with oral medications. “AbbVie is proud to deliver the first new treatment…